The Effect of Perioperative Ketamine on Acute and Chronic Pain After Major Back Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Postoperative Pain
Interventions
DRUG

Placebo

50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.

DRUG

Ketamine

50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.

Trial Locations (1)

1211

University Hospital of Geneva, Geneva

All Listed Sponsors
lead

University Hospital, Geneva

OTHER

NCT00618423 - The Effect of Perioperative Ketamine on Acute and Chronic Pain After Major Back Surgery | Biotech Hunter | Biotech Hunter